glaxosmithkline
-
Prestigious GlaxoSmithKline IMPACT Award, Awarded to LASS
glaxosmithkline 2h ago
-
Want A Lobotomy? Take Antidepressants!
glaxosmithkline 1d ago
-
Esther McVey MP visits Project SEARCH at GlaxoSmithKline - Disability Confident
glaxosmithkline 4d ago
-
GSK: Revamped R&D Approach Bearing Fruit
glaxosmithkline 6d ago
-
Turning Compliance from a Cost into an Asset
glaxosmithkline 1w ago
-
Charity teams up with pharma giant GSK in Africa
glaxosmithkline 1w ago
-
Charity teams up with pharma giant GSK in Africa
glaxosmithkline 1w ago
-
GlaxoSmithKline
glaxosmithkline 2w ago
-
Swine Flu Vaccine Reaction, Crooked Ireland, Medical System, GlaxoSmithKline, Health,
glaxosmithkline 2w ago
-
How Genomics and Bioinformatics are Changing the Practice and Business of Medicine
glaxosmithkline 2w ago
-
GSK accused of market 'abuse'
glaxosmithkline 3w ago
-
Piensalo de nuevo 4
glaxosmithkline 3w ago
-
Avalon's Jay Lichter & GSK's Lon Cardon on biotech deal
glaxosmithkline 3w ago
-
Paul Kavanagh's Market Update, 22 April 2013
glaxosmithkline 4w ago
-
Ribena 1L Premium Singapore
glaxosmithkline 4w ago
-
Session 2: Entrepreneurship in Science and Technology
glaxosmithkline 4w ago
-
GSK accused of market 'abuse'
glaxosmithkline 1mo ago
-
Paxil Birth Defects Lawsuits and Lawyers - Call 1-800-860-6742 Now!
glaxosmithkline 1mo ago
-
Success Stories - Opening up collaboration and beyond IP (GlaxoSmithKline and the Structural Genomics Consortium
glaxosmithkline 1mo ago
-
Preview of my talk on the future of patient data at TEDx O'Porto - Sat April 13th
glaxosmithkline 1mo ago
-
Gov. Perry Announces Major Biopharmaceutical Partnership
glaxosmithkline 1mo ago
-
HealthXL TV -- Interview with HealthXL mentor David Gibson
glaxosmithkline 2mo ago
-
Genetics, epigenetics and disease
glaxosmithkline 3mo ago
-
Glaxo's CEO Predicts Growth in 2013
glaxosmithkline 3mo ago
-
Wellbutrin XL TV Ad (2005)
glaxosmithkline 3mo ago
-
AstraZeneca PLEASE SET THE BEAGLES FREE NOW !
glaxosmithkline 3mo ago
-
Craig Yetter GlaxoSmithKline V5
glaxosmithkline 4mo ago
-
GSK Consumer Healthcare lanza NiQuitin, la última terapia sustitutiva para ayudar a dejar de fumar
glaxosmithkline 4mo ago
-
Valtrex TV Ad (2000)
glaxosmithkline 4mo ago
Tags
- aids
- award ceremony
- best practice
- board of trustees
- breaking down
- carry on
- carry out
- chris kelly
- climate
- comic relief
- corporate responsibility
- football
- glaxosmithkline
- health
- health service
- healthy living
- high level
- hiv
- last night
- leicester
- local communities
- london
- medical director
- mental health
- museums
- public health
- science
- science museum
- slow down
- social enterprise
- the award
- the journalist
- the reputation
- third sector
- trains
- united kingdom
Description
Leicestershire AIDS Support Services has won a prestigious GlaxoSmithKline IMPACT Award for its outstanding contribution to improving health in Leicestershire, GSK and The King's Fund announced last night at the award ceremony held at London's Science Museum. LASS provides rapid HIV testing, support, information and advocacy to people affected by HIV and AIDS in one of the most diverse areas in England. Leicester has many different communities and an above average population of HIV positive people. To slow down the spread of HIV and help people to access treatment, LASS invests in rapid testing services in community settings. There is particularly low uptake in some African communities, so LASS trains volunteers from these communities to carry out testing and provide information. They provide testing at a range of events and venues including African football tournaments to reach people who otherwise wouldn't be tested. LASS also provides services for people with the virus and maybe coping with other issues like poor mental health, and they provide healthy living training. The GSK IMPACT Awards, GSK's flagship UK corporate responsibility programme organised in partnershop with The King's Fund, is seen as a 'seal of excellence' in the sector. As well as as receiving £30,000 in funding during a difficult financial climate, the winners can take part in a training programme hosted by The King's Fund that provides training, development and networking opportunities. Feedback has shown that this opportunity is as important to the winning charities as the funding as it helps them develop the skills to carry on building their organisation. Katie Pinnock, Director of UK Corporate Contributions at GSK, OR Lisa Weaks, Third Sector Programme Manager at The King's Fund said: 'Congratulations to LASS, a strong winner in these awards. Their work providing, support for people with HIV and bringing testing into local communities, is making a real difference tobpeople lives in hard-to-reach groups. It is sharing best practice to further improve outcomes for its service users as well.' Patrick Bowe, Chair of LASS Board of Trustees , said: We are absolutely delighted to be recognised at this high level for the impact of our local work supporting and empowering people living with HIV, and challenging and breaking down stigma and discrimination. Our community HIV testing programme is contributing to government public health targets and has already saved the health service more than £3million through encouraging more people to have an HIV test and know their HIV status. This huge achievement for Leicester, Leicestershire and Rutland is due to the continued commitment by a great team of staff and volunteers. They are determined to deliver the highest standard of services possible and make a significant diference in HIV provision locally with a relatively small budget. This award will make a significant difference to the profile of our work and the reputation of LASS and our new social enterprise. The calibre of award is reflected in its judging panel who chose the winners, which this year includes Professor Steve Field, Deputy National Medical Director at NHS England (health inequalities); the journalist, Fiona Philips; Peter Wanless, CEO of The Big Lottery; Gilly Green, Head of UK Grants at Comic Relief; Sir Christopher Gent, Chairman of GSK; and, Sir Chris Kelly, Chair of The King's Fund.
